OR WAIT null SECS
June 11, 2020
The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.
June 08, 2020
Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.
June 05, 2020
The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.
Johnson & Johnson’s Janssen Pharmaceutical Companies has received a positive opinion in Europe for its two-dose Ebola vaccine regimen.
The collaboration will focus on novel therapeutics targeting RNA-modifying proteins for cancer treatment.
June 04, 2020
The investment will give the company the opportunity to accelerate the development of proprietary boron-10 target drugs while it develops its neutron beam accelerator technology for Boron Neutron Capture Therapy.
Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.
The new vaccine would be made with a Newcastle disease virus vector that expresses the immunogenic spike protein of SARS-CoV-2
The Gavi advance market commitment for COVID-19 vaccines is a new financing instrument aimed at incentivizing vaccine manufacturers to produce sufficient and affordable quantities of COVID-19 vaccines.
June 03, 2020
The medicine is the first outcome of the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.